Skip to main content
. 2011 Feb 25;2(3):449–455. doi: 10.3892/etm.2011.218

Table IV.

Clinical outcome.

MO17974 trial
ML18511 trial
Erlotinib dose (mg)
Response 100 125 150 100 150a
PR 2 1 - 3 1
SD 1 2 5 1 1
PD - - 1 2 -
a

One patient in this cohort was not evaluable for response.

PR, partial response; SD, stable disease; PD, progressive disease.